12:00 AM
 | 
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Adcetris brentuximab vedotin: Interim Phase I data

Seattle Genetics reported interim data from 17 evaluable patients with newly diagnosed systemic ALCL and other CD30-positive mature T cell lymphomas in an open-label Phase I trial evaluating 1.8 mg/kg Adcetris every 3 weeks given either sequentially with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) or concurrently with CH-P chemotherapy (cyclophosphamide, doxorubicin and prednisone). In 12 evaluable patients in the sequential Adcetris-CHOP chemotherapy regimen, all patients achieved an objective response, including 4 complete remissions and 8 partial remissions, after 2 cycles of single-agent Adcetris. Of the 6 evaluable patients who completed 6...

Read the full 436 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >